Argobio and the Institut Pasteur have launched Enodia Therapeutics, a French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections. Enodia’s first-in-class treatments target the translocon, a key gateway for protein secretion in the cell. “With the convergence of an unprecedented diverse… Read More
Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD). TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to… Read More
Dr Benedict Cross, CTO, PhoreMost, explores the drug discovery potential that targeted protein degradation (TPD) offers. The ubiquitin proteasome pathway (UPP) has been a subject of interest for therapeutic intervention since the first proteasome inhibitors to treat multiple myeloma were developed and approved in 2015. The targeted recruitment of… Read More
Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 programme, a splice variant of the AR. Read More
Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which… Read More
A paper in the journal Science has identified a new class of BTK mutations that are susceptible to NX-2127, a novel BTK and IKZF1/3 degrader. The study ‘Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127’ elucidates a previously unappreciated oncogenic scaffold function… Read More
Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor (ER) protein. Fast Track… Read More
A new webinar ‘Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift‘, brought to you by NanoTemper, is now available to watch on-demand. As more and more R&D pipelines include PROTAC candidates — the race to bring successful and… Read More
As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated. Watch this on-demand webinar to learn: How Spectral… Read More
A new Guide is now available for download from NanoTemper. The development of a successful PROTAC candidate requires overcoming challenges at each stage of development. Read this guide to learn about common roadblocks, technologies to overcome them, and how to ensure you’re on the right track to building an efficient… Read More
The development of a successful PROTAC candidate requires overcoming challenges at each stage of development. Read this guide to learn about common roadblocks, technologies to overcome them, and how to ensure you’re on the right track to building an efficient protein degrader. Download this guide to learn about: The most… Read More
NanoTemper outlines four questions to ask yourself to ensure you’re on the right track. Working in PROTACs, you’re tasked with the most challenging targets — that aim to address intractable diseases such as cancer, Alzheimer’s, or Parkinson’s disease. Despite the impressive promise of PROTACs, you still have to overcome many… Read More
